Eli Lilly’s Stock Momentum Faces a Test

Eli Lilly & Co. made corporate history by becoming the first pharmaceutical firm to surpass a $1 trillion market valuation. However, the initial euphoria surrounding this milestone has given way to a more cautious tone in recent trading sessions. Investors are now taking profits, applying noticeable downward pressure on the share price. Following a substantial rally in November, the market is questioning whether this represents a healthy consolidation or the beginning of a more sustained shift in sentiment.

The dominant theme in recent action has been profit-taking, coming on the heels of a powerful November surge that delivered double-digit percentage gains. Shares have retreated, closing last Friday with a decline of approximately Read more...